"Methoxsalen"

Clinical and dermoscopic assessment of the efficacy of topical trichloroacetic acid 70% versus methoxsalen 0.2% paint in stable acral vitiligo. Loss and absence of melanocytes due to a number of factors is responsible for vitiligo; known to be the commonest disorder of pigmentation. The aim of the study was to assess clinically and dermoscopically the efficacy of topical trichloroacetic acid 70 % versus methoxsalen 0.2% paint in stable acral vitiligo. The patients were randomly divided into 2 groups. Group a (n = 35) received topical 0.2% methoxsalen every other day for 4 months duration with dermoscopic follow up while group b (n = 35) received received topical TCA 70% application at the clinic every two weeks for 4 months with dermoscopic follow up. The majority of subjects in both groups

A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. This trial explores SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) METHODS: Forty-nine patients were randomized to daily 460 or 920 mg oral SM-88 with MPS

Methoxsalen An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationNo information is available on the use of methoxsalen during breastfeeding. Expert opinion indicates that due to the photosensitizing effects of methoxsalen, breastfeeding should be withheld for 24 hours after an oral dose to allow for 95% of the drug to be eliminated in the mother's urine.[1,2] The same precaution probably applies to patients receiving methoxsalen

Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. The investigation of extracorporeal photopheresis (ECP) plus standard of care (SoC) (SoC+ECP) in chronic graft-versus-host disease (cGVHD) within prospective, randomized clinical studies is limited, despite its frequent clinical use. This phase 1/pilot study was the first ). No TEAEs or SAEs were considered related to the ECP instrument or methoxsalen. The encouraging short-term results of this study could inform the design of subsequent studies. This trial was registered at www.clinicaltrials.gov as #NCT01380535.

Methoxsalen-induced macular toxicity Psoralen compounds such as methoxsalen are photosensitizer agents used in conjunction with ultraviolet A (UVA) radiation exposure as photochemotherapy (Psoralens and ultraviolet-A therapy [PUVA therapy]) for certain epidermal skin disorders such as psoriasis and vitiligo. Methoxsalen has been shown to be associated with premature cataract formation by forming been no reports in the literature of any posterior segment ocular toxicity arising from methoxsalen use. Here, we describe a case of a bilateral macular toxicity in a middle-aged male treated with methoxsalen for vitiligo.

The Adverse Effects of Methoxsalen on The Oogenesis of Balb/C Mice Methoxsalen is a natural photoactive compound which is found in many seed plants. A number of epidermal proliferative disorders can be treated by methoxsalen along with long wave ultraviolet A (UVA). In an experimental study, we aimed to demonstrate the effect of methoxsalen, UVA and their combination on oogenesis Balb/C mice . There were two experimental groups and a control group. The experimental groups were composed of i. a short term group with treatment duration of 15 days and ii. a long term group with treatment duration of 5 weeks. Both the long term and short term experimental groups were further subdivided into a UVA group, a methoxsalen group and a methoxsalen plus UVA group. After treatment, mature females

Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor The use of novel oral nicotine delivery devices and compositions for human consumption and for animal research studies has been increasing in the last several years. Studies were undertaken to examine whether the systemic administration of methoxsalen , an inhibitor of human CYP2A6 and mouse CYP2A5, would modulate nicotine pharmacokinetics and pharmacological effects (antinociception in the tail-flick, and hot-plate tests, and hypothermia) in male ICR mouse after acute oral nicotine administration. Administration of intra peritoneal (ip) methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine

, direct comparison: guselkumab vs. adalimumab (multipage table) Study Intervention Comparison Non-permitted concomitant treatment:  topical treatments that may influence the psoriasis (such as corticosteroids, tar, anthralin, calcipotriol, tazarotene, methoxsalen, pimecrolimus, tacrolimus, traditional Taiwanese, Korean or Chinese substances)  phototherapy  systemic treatment for psoriasis

a patient’s leukocytes are collected and treated ex vivo with methoxsalen and UVA light and then returned to the patient (Photopheresis is also performed with open systems, also known as two-step methods, which are characterised by different devices for cell separation and drug photo activation). In these systems the combination of the device for separation and the device for photoactivation has not been of methoxsalen, and reinfusion of the treated cells back into the patient within an automated and fully integrated process. All components of the treatment are validated for use together.Description of Medical ConditionChronic graft vs host disease (cGVHD) can occur in patients undergoing allogeneic transplant procedures. This event originates from donated bone marrow or peripheral blood stem cells that view

seen in people treated heavily with methoxsalen (psoralen) and ultraviolet A (PUVA) for psoriasis (3 of 1,380 patients, 0.2%). This has also been seen in individuals with chronic immune suppression, especially from chronic lymphocytic leukemia, HIV, and previous solid organ transplant.[16,24]In 2008, a novel polyomavirus (Merkel cell polyoma virus [MCPyV]) was first reported in MCC tumor specimens with methoxsalen and ultraviolet A radiation. N Engl J Med 339 (17): 1247-8, 1998. [PUBMED Abstract]Feng H, Shuda M, Chang Y, et al.: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 (5866): 1096-100, 2008. [PUBMED Abstract]Garneski KM, Warcola AH, Feng Q, et al.: Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J

either disease progression or unacceptable toxicity while on this treatment; and (c) the treatment must be in combination with use of ex-vivo injectable methoxsalen; and (d) the treatment must be under the supervision of a specialist haematologist. Benefit is claimable once per cycle of ECP treatment, regardless of the number of consecutive days over which each cycle is performed. 2 Consumer summary ) or immunotherapy (treatment that boosts the body’s own immune response against the cancer). ECP is a type of treatment that involves attaching a patient to a machine that removes some of their blood. The machine separates the white blood cells, and the red blood cells and plasma go back into the body. The white blood cells are mixed with a drug called methoxsalen, exposed to ultraviolet (UV) light, then put back

its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application The codependent application requested:  Medicare Benefits Schedule (MBS) listing for extracorporeal photopheresis (ECP) for erythrodermic (stage T4, M0) cutaneous T-cell lymphoma (CTCL); and  Pharmaceutical Benefits Schedule (PBS) listing for methoxsalen (UVADEX®). 2. MSAC’s advice to the Minister After considering the available evidence presented in relation to safety, clinical effectiveness and cost-effectiveness of extracorporeal photopheresis (ECP) with methoxsalen for treatment of refractory erythrodermic (stage T4M0) cutaneous T-cell lymphoma (CTCL), MSAC deferred its advice on public funding pending a revision of the economic model. MSAC accepted there was a high unmet clinical

that is specially constructed for this procedure. White blood cells are exposed to ultraviolet A (UVA) light in a separate plastic chamber and then returned to the patient.(3) In the past, patients treated with ECP were given oral 8-methoxypsoralen (8-MOP; methoxsalen) before the blood was leukapheresed.(1) Thus, during the ECP treatment, patients typically experienced untoward . However, the two techniques have not been directly compared in a clinical setting. In a closed ECP apparatus (one-step method), the blood cell separation, drug photoactivation, and reinfusion stages are fully integrated and automated, and all elements are approved for their combined use, including methoxsalen, a photoactivating agent (Table 2). There is no risk

mice, which could favor hepatocyte necrosis and infiltration of inflammatory cells. A total of 70 nonliver protective compounds were identified and screened. The results of network pharmacology illustrated that methoxsalen, obacunone, limonin, and dictamnine might be the main compounds that caused liver damage. The potential hepatotoxicity mechanisms of KP might be through the IL17 and apoptosis pathways to regulate IL6, TNF, CASP3, and CASP8 targets, thereby causing inflammation, excessive release of factors, and hepatocyte necrosis. The results of the ELISA experiments indicated that KP could increase the release of IL6 and TNF inflammatory factors in liver tissues. Molecular docking suggested that methoxsalen, obacunone, limonin, and dictamnine had moderate binding ability with CASP3

with population mean are considered. Methoxsalen, in combination with long-wave UVA radiation, is used in the symptomatic management certain psoriasis. The study was aimed to establish the bioequivalence (BE) of a newly developed methoxsalen capsule (MTX test) with that of a reference methoxsalen capsule (MTX reference) using multiple BE methods (i.e., average [ABE], population [PBE], and individual [IBE

of Use during LactationIn general, laser therapy and phototherapy are considered acceptable during breastfeeding.[1] Phototherapy for psoriasis is also generally acceptable; however, nursing should be withheld for 24 hours after ingestion of an oral psoralen, such as methoxsalen.[2]Laser therapy was used in some Russian and Austrian studies to prevent and treat lactation mastitis and nipple fissures.[3

. Indexing StatusSubject indexing assigned by NLMMeSHChronic Disease; Humans; Methoxsalen /therapeutic use; Photochemotherapy; Photosensitizing Agents /therapeutic use; Psoriasis /drug therapy; Randomized Controlled Trials as Topic; Ultraviolet RaysAccessionNumber12012022316Date bibliographic record published11/10/2012Date abstract record published02/05/2013Record StatusThis is a critical..

, the photoactivation of mononuclear cells (MNCs) using ultraviolet A (UVA) light and methoxsalen is believed to be the predominant initiating process. The effects of MNC passage through the instrument without photoactivation are unknown. The objective of this study was to evaluate the effect of cell processing through the photopheresis instruments on MNCs. Fourteen healthy male subjects underwent one simulated ECP for cell separation and processing of the BC in the absence of photoactivation do not induce a significant amount of apoptosis compared to the standard ECP with methoxsalen and UVA photoactivation.

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer Due to the subject's lack of conventional treatment options, a treatment plan using X-PACT administered intra-tumorally is proposed. X-PACT (X-ray Psoralen Activated Cancer Therapy) is comprised of a phosphor device (an energy modulation agent), methoxsalen sterile solution (a psoralen), X-ray energy and represents a potential new approach for the treatment of solid tumors. Methoxsalen is a psoralen found in the seeds of the Ammi majus (Umbelliferae) plant. Importantly, methoxsalen (whether formulated as the sterile solution \[Uvadex®\] or as a hard gelatin capsule \[8-MOP®\]) can promote a strong long-term clinical response, as observed in the treatment of cutaneous T cell lymphoma (CTCL) utilizing extracorporeal